Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol

British Journal of Pharmacology

Volumn 158, Issue 1, 2009, Pages 183-194

  Szczuka, A ^a   Wennerberg, M ^b   Packeu, A ^a   Vauquelin, G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Bronchodilation; Diffusion microkinetic model; Exosites; Reassertion; Rebinding; Salmeterol; Simulations

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; SALMETEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CANNABINOID 1 RECEPTOR; DRUG DERIVATIVE; SALBUTAMOL;

ARTICLE; BETA ADRENERGIC STIMULATION; BRONCHODILATATION; COMPUTER MODEL; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIMULATION; BIOLOGICAL MODEL; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; CELL LINE; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 69249205472     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00296.x     Document Type: Article

References (54)

1. Anderson GP (1993). Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci 52 : 2145 2160.
2. Anderson GP, Lindén A, Rabe KF (1994). Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7 : 569 578.
3. Andrews SS (2004). Serial rebinding of ligands to clustered receptors as exemplified by bacterial chemotaxis. Phys Biol 2 : 111 112.
4. Austin RP, Barton P, Bonnert RV, Brown RC, Cage PA, Cheshire DR et al. (2003). QSAR and the rational design of long-acting dual D2-receptor/beta2- adrenoceptor agonists. J Med Chem 46 : 3210 3320.
5. Bader R, Bettio A, Beck-Sickinger AG, Zerbe O (2001). Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection J Mol Biol 305 : 307 329.
6. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M et al. (1991). Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104 : 665 671.
7. Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH, Hendrick DJ (1993). A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholineinduced bronchoconstriction. Pulm Pharmacol 5 : 133 135.
8. Bergendal A, Lindén A, Skoogh B-E, Gerspacher M, Anderson GP, Lolfdahl C-G (1996). Salmeterol mediated reassertion of relaxation persists in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Br J Pharmacol 117 : 1009 1015.
9. Castanho MARB, Fernandes MX (2006). Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the 'membrane catalysis' model. Eur Biophys J 35 : 92 103.
10. Chester DW, Herbette LG, Mason RP, Joslyn AF, Triggle DJ, Koppel DE (1987). Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers. Biophys J 52 : 1021 1030.
11. Clark RB, Allal C, Friedman J, Johnson MB (1996). Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol Pharmacol 49 : 182 189.
12. Coleman RA, Johnson M, Nials AT, Vardey CJ (1996). Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol Sci 17 : 324 330.
13. DeLisi C (1981). The effect of cell size and receptor density on ligand-receptor reaction rate constants. Mol Immunol 18 : 507 511.
14. DeLisi C, Wiegel FW (1981). Effect of nonspecific forces and finite receptor number on rate constants of ligand - cell bound-receptor interactions. Proc Natl Acad Sci U S A 78 : 5569 5572.
15. 3H]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol 367 : 413 422.
16. Goldstein B, Posner RG, Torney DC, Erickson J, Holowka D, Baird B (1989). Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys J 56 : 955 966.
17. Gopalakrishnan M, Forsten-Williams K, Nugent MA, Täuber UC (2005). Effects of receptor clustering on ligand dissociation kinetics: theory and simulations. Biophys J 89 : 3686 3700.
18. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB (1996). Sustained activation of a G-protein - coupled receptor via anchored agonist binding. J Biol Chem 271 : 24029 24035.
19. Herbette LG (1994). Membrane pathways for drug/lon channel interactions: molecular basis for pharmacokinetic properties. Drug Devel Res 33 : 214 224.
20. Hrabctová S, Nicholson C (2004). Contribution of dead-space microdomains to tortuosity of brain extracellular space. Neurochem Int 45 : 467 477.
21. Isogaya M, Yamagiwa Y, Fujita S, Sugimoto Y, Nagao T, Kurose H (1998). Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. Mol Pharmacol 54 : 616 622.
22. Jack D (1991). A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoceptor agonists. Br J Clin Pharmacol 31 : 501 514.
23. Jeppsson AB, Lofdahl CG, Waldeck B, Widmark E (1989). On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulm Pharmacol 2 : 81 85.
24. Johnson M (2001). Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr Respir Rev 2 : 57 62.
25. Johnson M (2006). Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117 : 18 24.
26. 2-adrenoceptor agonists. In : Busse WW, Holgate ST (eds). Asthma & Rhinitis. Blackwell : Cambridge, pp. 1278 1295.
27. Johnson M, Butchers PR, Coleman RA, Nials AT, Strong P, Sumner MJ et al. (1993). The pharmacology of salmeterol. Life Sci 52 : 2131 2143.
28. Kirkham TC (2008). Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies? Cell Metab 7 : 68 78.
29. 1 antagonism and insurmountability: comparison of olmesartan and telmisartan. Brit J Pharmacol 151 : 952 962
30. Lindén A, Bergendal A, Ullman A (1991). High concentrations of formoterol and salmeterol in the guinea-pig trachea - reassertion of smooth muscle relaxation after beta-blockade followed by washout. Am Rev Respir Dis 143 : A749.
31. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER (2001). Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 90 : 1324 1335.
32. McCloskey MA, Poo MM (1986). Rates of membrane - associated reactions: Reduction of dimensionality revisited. J Cell Biol 102 : 88 96.
33. 2- adrenoceptor agonist mediating cyclic AMP accumulation in a neural cell line. Br J Pharmacol 110 : 619 626.
34. McCrea KE, Hill SJ (1996). Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor. Mol Pharmacol 49 : 927 923.
35. Maesen FPV, Smeets JJ, Gubblemans HHL, Zveers PMGA (1990). Bronchodilator effects of inhaled formoterol vs salbutamol over 12 hours. Chest 97 : 590 594.
36. Mason RP, Rhodes DG, Herbette LG (1991). Re-evaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model of drug interactions with biological membranes. J Med Chem 34 : 869 877.
37. Naline E, Zhang Y, Qian Y, Mairon N, Anderson GP, Grandordy B et al. (1994). Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 7 : 914 920.
38. Nials AT, Coleman RA, Johnson M, Magnussen H, Rabe KF, Vardey CJ (1993a). Effects of β-adrenoceptor agonists in human bronchial smooth muscle. Br J Pharmacol 110 : 1112 1116.
39. 2- adrenoceptor agonist, salmeterol. Br J Pharmacol 108 : 507 515.
40. Nials AT, Ball DI, Butchers PR, Coleman RA, Humbles AA, Johnson M et al. (1994). Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 251 : 127 135.
41. Okamoto T, Schlegel A, Scherer PE, Lisanti MP (1998). Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem 273 : 5419 5422.
42. 2L- receptor interactions in intact cells. Biochem Pharmacol 75 : 2192 2203.
43. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J (1997). Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10 : 2484 2489.
44. Posner RG, Lee B, Conrad DH, Holowka D, Baird B, Goldstein B (1992). Aggregation of IgE-receptor complexes on rat basophilic leukemia cells does not change the intrinsic affinity but can alter the kinetics of the ligand-IgE interaction. Biochem 31 : 5350 5356.
45. Rhodes DG, Newton R, Butler R, Herbette L (1992). Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol 42 : 596 602.
46. Rong Y, Arbabian M, Thiriot DS, Seibold A, Clark RB, Ruoho AE (1999). Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. Biochem 38 : 11278 11286.
47. Schwyzer R (1995). 100 years lock-and-key concept: are peptide keys shaped and guided to their receptors by the target cell membrane? Biopolymers 37 : 5 16.
48. Steinberg SF (2004). beta(2)-Adrenergic receptor signaling complexes in cardiomyocyte caveolae/lipid rafts. J Mol Cell Cardiol 37 : 407 415.
49. 2-adrenoceptors. Br J Pharmacol 100 : 489P.
50. Teschemacher A, Lemoine H (1999). Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 288 : 1084 1092.
51. Tummino PJ, Copeland RA (2008). Residence time of receptor-ligand complexes and its effect on biological function. Biochem 47 : 5481 5492.
52. Vauquelin G, Morsing P, Fierens FL, De Backer JP, Vanderheyden PM (2001). A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol 61 : 277 284.
53. Vauquelin G, Van Liefde I (2006). From slow antagonist dissociation to long-lasting receptor protection. Trends Pharmacol Sci 27 : 355 359.
54. 2- adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, Vrije Universiteit Amsterdam, The Netherlands.